Cart
sales@molnova.com
AP26113
CAS No. 1197958-12-5
AP26113( —— )
Catalog No. M10707 CAS No. 1197958-12-5
AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 44 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 92 | In Stock |
|
| 50MG | 137 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAP26113
-
NoteResearch use only, not for human use.
-
Brief DescriptionAP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay.
-
DescriptionAP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK| EGFR (C797S/del19)| EGFR (del19)| EGFR (del19)| IGF-1R
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1197958-12-5
-
Formula Weight529.01
-
Molecular FormulaC26H34ClN6O2P
-
Purity>98% (HPLC)
-
SolubilityEthanol: 106 mg/mL (200.37 mM); DMSO: 45 mg/mL (85.06 mM)
-
SMILESCOC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sen Zhang, et al. Y Research: April 15, 2010; Volume 70, Issue 8, Supplement 1
molnova catalog
related products
-
8-Bromo-cAMP(sodium ...
8-Bromo-cAMP is a long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.
-
5-phenylthieno[2,3-d...
5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
-
GSK1838705A
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
